Polaris’ ADI‑PEG 20 Featured in International Journal of Cancer Article: Novel Treatment for Pancreatic Cancer

Polaris’ collaborators at the University of California, Davis have published an article on ADI‑PEG 20 in the October 15th issue of International Journal of Cancer.

Article Title:
Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase

Authors:
Tawnya L. Bowles, Randie Kim, Joseph Galante, Colin M. Parsons, Subbulakshmi Virudachalam, Hsing-Jien Kung, Richard J. Bold

Journal Issue:
International Journal of Cancer: 123, 1950-1955 (2008)

Summary:
This study evaluated the level of argininosuccinate synthetase expression in pancreatic cancer and the effect of arginine deprivation, by ADI‑PEG 20, on cell growth. After examining argininosuccinate synthetase expression in 47 malignant and 20 non-neoplastic pancreatic tissues as well as in a panel of human pancreatic cancer cell lines, the authors observed that 87% and 71%, respectively, have low expression of argininosuccinate synthetase. The authors furthermore found that arginine depletion via administration of ADI‑PEG 20 suppressed pancreatic cancer growth in vitro and in vivo. Lastly, they observed that ADI‑PEG 20 induced apoptosis in cell lines with low argininosuccinate synthetase expression.

Conclusions:
The authors conclude, since pancreatic cancers frequently have low expression of argininosuccinate synthetase, that ADI‑PEG 20 may prove to be a novel treatment for this type of cancer.

Richard Bold, M.D., the senior author of the study, is the Chief of Surgical Oncology at the UC Davis Cancer Center and the principal investigator for the American College of Surgeons Oncology Group (ACOSOG) at UC Davis. Dr. Bold, an expert in pancreatic and hepatobiliary cancers, is actively investigating new treatments for detecting and treating cancer.

About Polaris Group
Polaris Group is a privately held multinational biopharmaceutical company specializing in the research and development of protein drugs to treat cancer and other debilitating diseases. The company also utilizes a rational structure-based approach for the design of novel small molecule inhibitors of cancer-related protein targets.